Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines

David S. Ettinger; Douglas E. Wood; Wallace Akerley; Lyudmila A. Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T. Cheney; Lucian R. Chirieac; Thomas A. D'Amico; Todd L. Demmy; Thomas J. Dilling; M. Chris Dobelbower; Ramaswamy Govindan; Frederic W. Grannis; Leora Horn; Thierry M. Jahan; Ritsuko Komaki; Lee M. Krug; Rudy P. Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W. Loo; Renato Martins; Gregory A. Otterson; Jyoti D. Patel; Katherine M. Pisters; Karen Reckamp; Gregory J. Riely; Eric Rohren; Steven E. Schild; Theresa A. Shapiro; Scott J. Swanson; Kurt Tauer; Stephen C. Yang; Kristina Gregory; Miranda Hughes

doi:10.6004/jnccn.2015.0071

Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael LanutiRogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Houston Methodist

Research output: Contribution to journal › Review article › peer-review

355 Scopus citations

Abstract

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

Original language	English (US)
Pages (from-to)	515-524
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	13
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2015.0071
State	Published - May 1 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2015.0071

Cite this

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Dilling, T. J., Dobelbower, M. C., Govindan, R., Grannis, F. W., Horn, L., Jahan, T. M., Komaki, R., Krug, L. M., Lackner, R. P., ... Hughes, M. (2015). Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 13(5), 515-524. https://doi.org/10.6004/jnccn.2015.0071

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DR, Cheney, RT, Chirieac, LR, D'Amico, TA, Demmy, TL, Dilling, TJ, Dobelbower, MC, Govindan, R, Grannis, FW, Horn, L, Jahan, TM, Komaki, R, Krug, LM, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Rohren, E, Schild, SE, Shapiro, TA, Swanson, SJ, Tauer, K, Yang, SC, Gregory, K & Hughes, M 2015, 'Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 13, no. 5, pp. 515-524. https://doi.org/10.6004/jnccn.2015.0071

@article{19f0d3f2dc60453ebaae453aa391c540,

title = "Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines",

abstract = "These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.",

author = "Ettinger, \{David S.\} and Wood, \{Douglas E.\} and Wallace Akerley and Bazhenova, \{Lyudmila A.\} and Hossein Borghaei and Camidge, \{David Ross\} and Cheney, \{Richard T.\} and Chirieac, \{Lucian R.\} and D'Amico, \{Thomas A.\} and Demmy, \{Todd L.\} and Dilling, \{Thomas J.\} and Dobelbower, \{M. Chris\} and Ramaswamy Govindan and Grannis, \{Frederic W.\} and Leora Horn and Jahan, \{Thierry M.\} and Ritsuko Komaki and Krug, \{Lee M.\} and Lackner, \{Rudy P.\} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, \{Billy W.\} and Renato Martins and Otterson, \{Gregory A.\} and Patel, \{Jyoti D.\} and Pisters, \{Katherine M.\} and Karen Reckamp and Riely, \{Gregory J.\} and Eric Rohren and Schild, \{Steven E.\} and Shapiro, \{Theresa A.\} and Swanson, \{Scott J.\} and Kurt Tauer and Yang, \{Stephen C.\} and Kristina Gregory and Miranda Hughes",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2015",

month = may,

day = "1",

doi = "10.6004/jnccn.2015.0071",

language = "English (US)",

volume = "13",

pages = "515--524",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "5",

}

TY - JOUR

T1 - Non-Small cell lung cancer, version 6.2015

T2 - Featured updates to the NCCN guidelines

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David Ross

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'Amico, Thomas A.

AU - Demmy, Todd L.

AU - Dilling, Thomas J.

AU - Dobelbower, M. Chris

AU - Govindan, Ramaswamy

AU - Grannis, Frederic W.

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Krug, Lee M.

AU - Lackner, Rudy P.

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Rohren, Eric

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Swanson, Scott J.

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2015/5/1

Y1 - 2015/5/1

N2 - These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

AB - These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.

UR - https://www.scopus.com/pages/publications/84984590308

UR - https://www.scopus.com/inward/citedby.url?scp=84984590308&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2015.0071

DO - 10.6004/jnccn.2015.0071

M3 - Review article

C2 - 25964637

AN - SCOPUS:84984590308

SN - 1540-1405

VL - 13

SP - 515

EP - 524

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Non-Small cell lung cancer, version 6.2015: Featured updates to the NCCN guidelines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this